SAN DIEGO and
TORONTO, Nov. 17, 2014 /PRNewswire/ - Aptose Biosciences
Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing
new therapeutics and molecular diagnostics that target the
underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and
Chief Executive Officer, will present at the upcoming Stifel 2014
Healthcare Conference on November 19,
2014, at 8:35 a.m. ET, at The
New York Palace Hotel, New York.
Dr. Rice will provide a corporate overview of the Company's recent
activities and strategic direction including plans to develop
Aptose's lead clinical agent, APTO-253 for acute myeloid leukemia
(AML), myelodysplastic syndromes (MDS) and other hematologic
malignancies.
A live audio webcast of the presentation will be
accessible by visiting:
http://www.veracast.com/webcasts/stifel/healthcare2014/27213553963.cfm
The audio webcast will be archived shortly after
the live event and will be available for 90 days through the Aptose
website at www.aptose.com.
About Aptose Biosciences
Aptose Biosciences is a clinical-stage
biotechnology company committed to discovering and developing
personalized therapies that address unmet medical needs in
oncology. Aptose is advancing new therapeutics focused on
novel cellular targets on the leading edge of cancer research
coupled with companion diagnostics to identify the optimal patient
population for its products. Aptose's lead anticancer agent
APTO-253 is under development for AML, MDS and other hematologic
malignancies. For further information, please visit
www.aptosebiosciences.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Canadian and U.S. securities laws.
Such statements include, but are not limited to, statements
relating to the Company's plans, objectives, expectations and
intentions and other statements including words such as "continue",
"expect", "intend", "will", "should", "would", "may", and other
similar expressions. Such statements reflect our current views with
respect to future events and are subject to risks and uncertainties
and are necessarily based upon a number of estimates and
assumptions that, while considered reasonable by us are inherently
subject to significant business, economic, competitive, political
and social uncertainties and contingencies. Many factors could
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements described in this press release. Such expressed or
implied forward looking statements could include, among others: our
ability to obtain the capital required for research and operations;
the inherent risks in early stage drug development including
demonstrating efficacy; development time/cost and the regulatory
approval process; the progress of our clinical trials; our ability
to find and enter into agreements with potential partners; our
ability to attract and retain key personnel; changing market
conditions; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports
and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission.
Should one or more of these risks or
uncertainties materialize, or should the assumptions set out in the
section entitled "Risk Factors" in our filings with Canadian
securities regulators and the United States Securities and Exchange
Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described
herein. These forward-looking statements are made as of the date of
this press release and we do not intend, and do not assume any
obligation, to update these forward-looking statements, except as
required by law. We cannot assure you that such statements will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not
guarantees of future performance and accordingly investors are
cautioned not to put undue reliance on forward-looking statements
due to the inherent uncertainty therein.
SOURCE Aptose Biosciences Inc.
PDF available at:
http://stream1.newswire.ca/media/2014/11/17/20141117_C9714_DOC_EN_43208.pdf
